oral semaglutide novo nordisk Efficacy and safety of by subgroups of patient characteristics in the PIONEER phase 3 programme Novo Nordisk to Seek Approval

Dai X, Tan Y, Cai S, Xiong X, Wang L, Ye Q, Yan X, Ma K, Cai L

The FDA is expected to clear orfoglipron sometime in the second quarter of the year

This is a cause for concern, not a cause for alarm

Every state has its own requirements for establishing a valid prescriber-patient relationship via telehealth, and oversight is tightening (New Yorks May 2025 telehealth controlled-substance rules signal the direction)

They always keep the patient at the center and recommend what is good for the patient

Yes, FDA-approved generic medications must demonstrate bioequivalence to the brand-name version, meaning they have the same active ingredient and provide the same clinical benefits